DRIO Quote, Financials, Valuation and Earnings

National Research has a net margin of -126.67% compared to DarioHealth's net margin of 17.78%. DarioHealth's return on equity of -63.85% beat National Research's return on equity of 64.54%.

DarioHealth has a consensus price target of $2.67, signalling upside risk potential of 300.52%. On the other hand National Research has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth has higher upside potential than National Research, analysts believe DarioHealth is more attractive than National Research.

DarioHealth has a beta of 1.421, which suggesting that the stock is 42.08% more volatile than S&P 500. In comparison National Research has a beta of 0.469, suggesting its less volatile than the S&P 500 by 53.147%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research offers a yield of 3.24% to investors and pays a quarterly dividend of $0.12 per share. DarioHealth pays -- of its earnings as a dividend. National Research pays out -- of its earnings as a dividend.

DarioHealth quarterly revenues are $7.6M, which are smaller than National Research quarterly revenues of $36.9M. DarioHealth's net income of -$9.6M is lower than National Research's net income of $6.6M. Notably, DarioHealth's price-to-earnings ratio is -- while National Research's PE ratio is 14.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 0.94x versus 2.46x for National Research. Usually stocks with elevated PS ratios are considered overvalued.

Ontrak has a net margin of -126.67% compared to DarioHealth's net margin of -217.21%. DarioHealth's return on equity of -63.85% beat Ontrak's return on equity of -231.34%.

DarioHealth has a consensus price target of $2.67, signalling upside risk potential of 300.52%. On the other hand Ontrak has an analysts' consensus of $4.00 which suggests that it could grow by 177.78%. Given that DarioHealth has higher upside potential than Ontrak, analysts believe DarioHealth is more attractive than Ontrak.

DarioHealth has a beta of 1.421, which suggesting that the stock is 42.08% more volatile than S&P 500. In comparison Ontrak has a beta of 2.640, suggesting its more volatile than the S&P 500 by 163.958%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ontrak offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth pays -- of its earnings as a dividend. Ontrak pays out -- of its earnings as a dividend.

DarioHealth quarterly revenues are $7.6M, which are larger than Ontrak quarterly revenues of $2.6M. DarioHealth's net income of -$9.6M is lower than Ontrak's net income of -$5.6M. Notably, DarioHealth's price-to-earnings ratio is -- while Ontrak's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 0.94x versus 0.50x for Ontrak. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings has a net margin of -126.67% compared to DarioHealth's net margin of 10.75%. DarioHealth's return on equity of -63.85% beat Spok Holdings's return on equity of 9.43%.

DarioHealth has a consensus price target of $2.67, signalling upside risk potential of 300.52%. On the other hand Spok Holdings has an analysts' consensus of $20.00 which suggests that it could grow by 26.66%. Given that DarioHealth has higher upside potential than Spok Holdings, analysts believe DarioHealth is more attractive than Spok Holdings.

DarioHealth has a beta of 1.421, which suggesting that the stock is 42.08% more volatile than S&P 500. In comparison Spok Holdings has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.856%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings offers a yield of 7.92% to investors and pays a quarterly dividend of $0.31 per share. DarioHealth pays -- of its earnings as a dividend. Spok Holdings pays out 176.29% of its earnings as a dividend.

DarioHealth quarterly revenues are $7.6M, which are smaller than Spok Holdings quarterly revenues of $33.9M. DarioHealth's net income of -$9.6M is lower than Spok Holdings's net income of $3.6M. Notably, DarioHealth's price-to-earnings ratio is -- while Spok Holdings's PE ratio is 21.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 0.94x versus 2.35x for Spok Holdings. Usually stocks with elevated PS ratios are considered overvalued.